Table 2:
Independent predictors of SRE among mCRPC patients
| Model Selection* | |||
|---|---|---|---|
| Variables | HR | 95% CI | P |
| Treatment center | 0.17 | ||
| Center 1 | Ref. | ||
| Center 2 | 0.62 | 0.37-1.02 | |
| Center 3 | 0.75 | 0.45-1.26 | |
| Center 4 | 0.84 | 0.48-1.47 | |
| Center 5 | 1.16 | 0.80-1.70 | |
| Center 6 | 1.07 | 0.73-1.58 | |
| Center 7 | 0.76 | 0.43-1.34 | |
| Center 8 | 0.81 | 0.52-1.27 | |
| Bone pain | <0.001 | ||
| No | Ref. | ||
| Yes | 3.00 | 2.27-3.96 | |
| Unknown | 1.49 | 0.98-2.25 | |
| PSA at metastases | 1.07 | 0.98-1.17 | 0.13 |
| Years from ADT to CRPC | 0.94 | 0.91-0.98 | 0.004 |
| Years from CRPC to mets | 0.91 | 0.84-0.98 | 0.010 |
| Lymph node metastasis | 0.054 | ||
| No | Ref. | ||
| Yes | 0.69 | 0.48-1.01 | |
| Visceral metastasis | 0.013 | ||
| No | Ref. | ||
| Yes | 1.83 | 1.13-2.96 | |
ADT: androgen deprivation therapy; CI: confidence interval; CRPC: castration-resistant prostate cancer; HR: hazard ratio; SRE: skeletal-related event
*
Backwards stepwise selection with α=0.1 for entry and α=0.2 for removal